DE06252444T8 - 2-N-{5-[[4-[2-(Methyl-2-pyridinylamino)-ethoxy]-phenyl]-methyl]-2,4-thiazolidindion}-bernsteinsäure, Verfahren zur Herstellung und Zusammensetzungen mit Rosiglitazonmaleat - Google Patents

2-N-{5-[[4-[2-(Methyl-2-pyridinylamino)-ethoxy]-phenyl]-methyl]-2,4-thiazolidindion}-bernsteinsäure, Verfahren zur Herstellung und Zusammensetzungen mit Rosiglitazonmaleat Download PDF

Info

Publication number
DE06252444T8
DE06252444T8 DE06252444T DE06252444T DE06252444T8 DE 06252444 T8 DE06252444 T8 DE 06252444T8 DE 06252444 T DE06252444 T DE 06252444T DE 06252444 T DE06252444 T DE 06252444T DE 06252444 T8 DE06252444 T8 DE 06252444T8
Authority
DE
Germany
Prior art keywords
methyl
pyridinylamino
thiazolidinedione
ethoxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE06252444T
Other languages
English (en)
Other versions
DE06252444T1 (de
Inventor
Yeudit Dolitzky
Yoseph Avezov
Dina Spivak
Minutza Leibovici
Ben-Zion Solomon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of DE06252444T1 publication Critical patent/DE06252444T1/de
Application granted granted Critical
Publication of DE06252444T8 publication Critical patent/DE06252444T8/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE06252444T 2006-05-09 2006-05-09 2-N-{5-[[4-[2-(Methyl-2-pyridinylamino)-ethoxy]-phenyl]-methyl]-2,4-thiazolidindion}-bernsteinsäure, Verfahren zur Herstellung und Zusammensetzungen mit Rosiglitazonmaleat Active DE06252444T8 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06252444A EP1854794A1 (de) 2006-05-09 2006-05-09 2-N-{5-[[4-[2-(Methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedion} Bernsteinsäure, Verfahren zur Herstellung und Zusammensetzungen mit Rosiglitazon Maleat

Publications (2)

Publication Number Publication Date
DE06252444T1 DE06252444T1 (de) 2008-05-21
DE06252444T8 true DE06252444T8 (de) 2009-03-19

Family

ID=36997726

Family Applications (1)

Application Number Title Priority Date Filing Date
DE06252444T Active DE06252444T8 (de) 2006-05-09 2006-05-09 2-N-{5-[[4-[2-(Methyl-2-pyridinylamino)-ethoxy]-phenyl]-methyl]-2,4-thiazolidindion}-bernsteinsäure, Verfahren zur Herstellung und Zusammensetzungen mit Rosiglitazonmaleat

Country Status (4)

Country Link
EP (2) EP1854794A1 (de)
CY (1) CY2200159T2 (de)
DE (1) DE06252444T8 (de)
ES (1) ES2294980T1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR068925A1 (es) * 2007-10-17 2009-12-16 Medichem Sa Un proceso mejorado para preparar un derivado de 2,4. - tiazolidindiona
WO2010013141A2 (en) * 2008-08-01 2010-02-04 Actavis Group Ptc Ehf Substantially pure rosiglitazone hydrogen sulfate
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
JP2002504137A (ja) * 1997-06-18 2002-02-05 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー チアゾリジンジオンおよびメトホルミンを用いる糖尿病の治療
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
US20050112198A1 (en) * 2003-10-27 2005-05-26 Challapalli Prasad V. Bupropion formulation for sustained delivery

Also Published As

Publication number Publication date
ES2294980T1 (es) 2008-04-16
CY2200159T2 (el) 2010-07-28
EP2270007A1 (de) 2011-01-05
DE06252444T1 (de) 2008-05-21
EP1854794A1 (de) 2007-11-14

Similar Documents

Publication Publication Date Title
IL206201A (en) Salts of 2– {4 - [(3s) - piperidine – 3 – ram] phenyl} –2 h– indazole-7-carboxamide-compatible pharmaceuticals and their uses
IL220212A (en) Derivatives 5 - [(2-Aminopyrimide-4-Yl) Methylidan] -3,1-Thiazolidine-4,2-Discussion and Pharmaceutical Preparations Containing Them
IL195882A (en) Crystalline forms of derivatives of (1 s) –1, 5 – anhydro – 1– c - (3 - ((phenyl) methyl) phenyl) - d -glucitol with amino acids and their use in the treatment of diabetes
IL215094A (en) Methyl [1– {2– [5– (10– {2– [1– {2– [Methoxycarbonyl) Amino] –3 – Methylbutanoyl} pyrrolidin-2-yl] - h1– Amidazole-5-Ill} –6– Phenylindolo [2,1- c] [3,1] benzoxazine-3-yl) - h 1-amidazole-2-yl] pyrrolidin-1-yl} -3-methyl-1-oxobutan-2-yl] carbamate and preparations Hcv delay pharmacy containing it
DE502007001453D1 (de) 4,5-diphenyl-pyrimidinyl substituierte carbonsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
PL384446A1 (pl) Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2,4-tiazolidynodionu z kwasem malonowym i sposób jej wytwarzania
GB2454620B (en) Solid dosage form of olmesartan medoxomil and amlodipine
FI20060501L (fi) Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
ZA200902354B (en) Crystalline forms of thiazolidinedione compound and its manufacturing method
WO2010055119A3 (en) Pharmaceutical composition comprising pimobendan
IL194575A0 (en) Thiazolidinedione derivatives as pi3 kinase inhibitors
IL195348A0 (en) Crystalline form of (trans-4-[({5-[(3,4-difluorophenyl)amino]-1,3,4-oxadiazol-2-yl}carbonyl)amino]phenyl}cyclohexyl)acetic acid
ZA200903578B (en) Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
DE06252444T8 (de) 2-N-{5-[[4-[2-(Methyl-2-pyridinylamino)-ethoxy]-phenyl]-methyl]-2,4-thiazolidindion}-bernsteinsäure, Verfahren zur Herstellung und Zusammensetzungen mit Rosiglitazonmaleat
EP2035406A4 (de) Neue substituierte 1h-chinazolin-2,4-dionderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält
HK1140949A1 (en) Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl) phenyl]piperidine 4-[2-(4-)-]
DE112007001614A5 (de) Lignocellulosischer Zuschlagstoff und Verfahren zu seiner Herstellung
DE102008046198B8 (de) Implantat und Verfahren zu seiner Herstellung sowie deren Verwendung
IL188175A0 (en) 2-n-(5-[[4-(2-methyl-2-pyridinylamino)ethoxy] phenyl] methyl]-2,4-thiazolidinedione)butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
TWI368515B (en) Medical herb composition for promoting the growth of mammal's hairs and the manufacturing method thereof
PL385697A1 (pl) Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2, 4-tiazolidynodionu z kwasem 1, 5-naftalenodisulfonowym i sposób jej wytwarzania
HUP0600347A3 (en) Process for the preparation of {2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one (ziprasidon) and the intermediate
EP2017331A4 (de) Verfahren zur herstellung von s-adenosyl-l-methionin enthaltender trockenhefe mit ausgezeichneter lagerstabilität, deren produkt und zusammensetzung zur einnahme über den mund
EP2018104A4 (de) Verfahren und zusammensetzung zur verabreichung bioaktiver verbindungen aus morinda citrifolia
ITMI20060529A1 (it) Metodo per la determinazione dei polimorfismi lattoproteici nei bovini

Legal Events

Date Code Title Description
8596 Reprint of erroneous front page